Capital Research Global Investors
VRTX icon

Capital Research Global Investors’s Vertex Pharmaceuticals VRTX Stock Holding History

Capital Research Global Investors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.68B Sell
19,490,637
-1,635,327
-8% -$725M 1.35% 17
2026
Q1 		$9.43B Buy
21,125,964
+3,809,620
+22% +$1.78B 1.46% 14
2025
Q4 		$7.85B Buy
17,316,344
+763,063
+5% +$329M 1.45% 14
2025
Q3 		$6.48B Buy
16,553,281
+444,990
+3% +$186M 1.22% 17
2025
Q2 		$7.17B Buy
16,108,291
+1,571,947
+11% +$724M 1.44% 15
2025
Q1 		$7.05B Buy
14,536,344
+4,107,393
+39% +$1.91B 1.53% 13
2024
Q4 		$4.2B Buy
10,428,951
+1,426,746
+16% +$661M 0.86% 29
2024
Q3 		$4.19B Buy
9,002,205
+462,866
+5% +$222M 0.87% 31
2024
Q2 		$4B Buy
8,539,339
+2,795,457
+49% +$1.21B 0.88% 27
2024
Q1 		$2.4B Buy
5,743,882
+2,176,218
+61% +$920M 0.54% 48
2023
Q4 		$1.45B Buy
3,567,664
+195,080
+6% +$72.1M 0.36% 74
2023
Q3 		$1.17B Buy
3,372,584
+310,908
+10% +$109M 0.32% 78
2023
Q2 		$1.08B Buy
3,061,676
+2,251,781
+278% +$759M 0.29% 83
2023
Q1 		$255M Buy
+809,895
New +$243M 0.07% 191
2020
Q4 		– Sell
-1,250,658
Closed -$340M – 433
2020
Q3 		$340M Sell
1,250,658
-1
-0% -$276 0.1% 169
2020
Q2 		$363M Sell
1,250,659
-5
-0% -$1.36K 0.11% 152
2020
Q1 		$298M Buy
1,250,664
+15
+0% +$3.44K 0.12% 147
2019
Q4 		$274M Buy
1,250,649
+379
+0% +$76.7K 0.08% 192
2019
Q3 		$212M Buy
1,250,270
+22
+0% +$3.89K 0.07% 201
2019
Q2 		$229M Buy
1,250,248
+248
+0% +$43.4K 0.07% 191
2019
Q1 		$230M Sell
1,250,000
-815,018
-39% -$151M 0.07% 197
2018
Q4 		$342M Sell
2,065,018
-590,000
-22% -$102M 0.12% 158
2018
Q3 		$512M Buy
+2,655,018
New +$473M 0.15% 136

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Capital Research Global Investors's VRTX Position: Q2 2026 in Review

Capital Research Global Investors reduced its Vertex Pharmaceuticals (VRTX) stake by 7.7% in Q2 2026, selling an estimated $725M and leaving 19,490,637 shares worth $9.68B. The position accounts for 1.35% of the portfolio, ranked #17.

Capital Research Global Investors first reported a position in VRTX in Q3 2018 and has held it in 23 quarters since. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Capital Research Global Investors held 19,490,637 shares of Vertex Pharmaceuticals worth $9.68B as of Q2 2026.
  • Capital Research Global Investors sold 1,635,327 Vertex Pharmaceuticals shares in Q2 2026, an estimated $725M.
  • Vertex Pharmaceuticals made up 1.35% of Capital Research Global Investors's portfolio in Q2 2026, its #17 holding.
  • Capital Research Global Investors first reported a position in Vertex Pharmaceuticals in Q3 2018 and has held it in 23 quarters since.
  • 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Capital Research Global Investors's 13F filing for Q2 2026, filed 12 Aug 2026.